PDSB · Insider Trading
PDS Biotechnology Corporation Common Stock
Every open-market purchase and sale reported by PDSB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | John Andrew Dawson | Director | A | +22,700 deriv. | — |
| 2026-10-20 | Bruce Wendel | Director | A | +22,700 deriv. | — |
| 2026-10-20 | Deborah Ramsdell | Director | A | +22,700 deriv. | — |
| 2026-03-03 | Gregory Conn | Chief Scientific Officer | A | +150,000 deriv. | — |
| 2026-03-03 | Frank Bedu-Addo | President/CEO | A | +548,782 deriv. | — |
| 2026-03-03 | Stephan Toutain | Chief Operating Officer | A | +300,000 deriv. | — |
| 2026-03-03 | Lars Boesgaard | Chief Financial Officer | A | +300,000 deriv. | — |
| 2026-03-03 | Kamil Ali-Jackson | Director | A | +54,876 deriv. | — |
| 2026-03-03 | Ilian Iliev | Director | A | +54,876 deriv. | — |
| 2026-03-03 | Gregory Gene Freitag | Director | A | +54,876 deriv. | — |
| 2026-03-03 | Kirk V. Shepard | Chief Medical Officer | A | +300,000 deriv. | — |
| 2026-03-03 | Stephen C. Glover | Director | A | +54,876 deriv. | — |
| 2026-03-03 | Spencer D. Brown | Senior VP, General Counsel | A | +300,000 deriv. | — |
| 2026-03-03 | Otis W Brawley | Director | A | +54,876 deriv. | — |
| 2025-07-25 | Kirk V. Shepard | Chief Medical Officer | A | +150,000 deriv. | — |
| 2025-07-25 | Stephan Toutain | Chief Operations Officer | A | +150,000 deriv. | — |
| 2025-07-25 | Frank Bedu-Addo | President/CEO | A | +450,000 deriv. | — |
| 2025-07-25 | Spencer D. Brown | Senior VP, General Counsel | A | +206,000 deriv. | — |
| 2025-07-25 | Lars Boesgaard | Chief Financial Officer | A | +150,000 deriv. | — |
| 2025-07-25 | Gregory Conn | Chief Scientific Officer | A | +86,648 deriv. | — |
| 2025-06-11 | Ilian Iliev | Director | A | +22,700 deriv. | — |
| 2025-06-11 | Stephen C. Glover | Director | A | +22,700 deriv. | — |
| 2025-06-11 | Gregory Gene Freitag | Director | A | +22,700 deriv. | — |
| 2025-06-11 | Otis W Brawley | Director | A | +22,700 deriv. | — |
| 2025-06-11 | Kamil Ali-Jackson | Director | A | +22,700 deriv. | — |
| 2025-03-03 | Gregory Gene Freitag | Director | Buy | +15,060 | +$25.00K |
| 2025-03-03 | Stephen C. Glover | Director | Buy | +15,061 | +$25.00K |
| 2024-06-25 | Gregory Gene Freitag | Director | A | +9,000 deriv. | — |
| 2024-06-25 | Otis W Brawley | Director | A | +9,000 deriv. | — |
| 2024-06-25 | Ilian Iliev | Director | A | +9,000 deriv. | — |
| 2024-06-25 | Stephen C. Glover | Director | A | +9,000 deriv. | — |
| 2024-06-25 | Kamil Ali-Jackson | Director | A | +9,000 deriv. | — |
| 2024-06-25 | Richard Sykes | Director | A | +9,000 deriv. | — |
| 2024-05-02 | Stephan Toutain | Chief Operations Officer | A | +200,000 deriv. | — |
| 2024-01-23 | Kirk V. Shepard | Chief Medical Officer | A | +200,000 deriv. | — |
| 2023-12-04 | Lars Boesgaard | Chief Financial Officer | A | +200,000 deriv. | — |
| 2023-07-17 | Gregory Gene Freitag | Director | A | +9,000 deriv. | — |
| 2023-07-17 | Stephen C. Glover | Director | A | +9,000 deriv. | — |
| 2023-07-17 | Kamil Ali-Jackson | Director | A | +9,000 deriv. | — |
| 2023-07-17 | Otis W Brawley | Director | A | +9,000 deriv. | — |
| 2023-07-17 | Richard Sykes | Director | A | +9,000 deriv. | — |
| 2023-07-17 | Ilian Iliev | Director | A | +9,000 deriv. | — |
| 2023-01-06 | Gregory Conn | Chief Scientific Officer | A | +137,200 deriv. | — |
| 2023-01-06 | Lauren Wood | Chief Medical Officer | A | +110,800 deriv. | — |
| 2023-01-06 | Spencer D. Brown | Senior VP, General Counsel | A | +20,400 deriv. | — |
| 2023-01-06 | Frank Bedu-Addo | President/CEO | A | +385,300 deriv. | — |
| 2023-01-06 | Matthew C Hill | Chief Financial Officer | A | +161,200 deriv. | — |
| 2022-12-02 | Frank Bedu-Addo | President/CEO | MIXED | +44,351 | −$270.95K |
| 2022-06-29 | Otis W Brawley | Director | A | +9,000 deriv. | — |
| 2022-06-29 | Steve C Glover | Director | A | +9,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Frank Bedu-Addo | President/CEO | 690,866 | $735.77K |
| Stephen C. Glover | Director | 78,851 | $83.98K |
| Gregory Gene Freitag | Director | 61,213 | $65.19K |
| Kamil Ali-Jackson | Director | 11,764 | $12.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PDSB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.